Nuclear Transcription Factor Y Subunit Alpha (NFYA) is the sequence-specific DNA-binding subunit of the heterotrimeric NF-Y complex (comprising NFYA, NFYB, and NFYC). By binding highly specifically to the CCAAT box promoter element, NFYA regulates genes critical for cell cycle progression, metabolic rewiring, and stemness. Emerging as a compelling oncology target, particularly in triple-negative breast cancer (TNBC), gastric cancer, and colorectal cancer, therapeutic strategies are pivoting toward disrupting the NF-Y trimer assembly or utilizing PROTACs for targeted degradation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NFYA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NFYA Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW confirmed by SDS-PAGE. |
View NFYA Products |
| Gene Delivery | NFYA Promise-ORF / Lentivirus Full-length ORF sequence-verified lentiviral particles for stable cell line generation. |
View NFYA Products |
| Benchmark Ab | Anti-NFYA Recombinant Antibody Sequence-verified positive control for chromatin immunoprecipitation (ChIP) and Western Blot validation. |
View NFYA Products |
| Validator | NFYA siRNA Set Target-specific siRNA pool for target knockdown and specificity verification. |
View NFYA Products |
| Related Target A | NFYB Essential partner subunit forming the NF-Y histone-like dimer prior to NFYA binding. |
View NFYB Products |
| Related Target B | NFYC Crucial heterotrimeric partner; co-targeting or co-expression is necessary for structural reconstitution assays. |
View NFYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Functional Heterotrimer | Highly pure, sequence-verified NFYA, NFYB, and NFYC recombinant proteins available for in vitro assembly assays. |
| Sequence Fidelity & Mutation Mapping | All plasmid and lentiviral constructs are 100% sequence verified to ensure correct splicing isoforms. |
| Lack of Validated Control Reagents | Sequence-defined recombinant benchmark antibodies included for assay standardization. |
| Off-Target Assessment | Validated siRNA sets included to confirm phenotype specificity post-knockdown. |
Live NFYA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NFYA therapeutics is intensifying, with major players shifting focus from traditional genetic knockdown studies to small-molecule inhibitors of protein-protein interactions (PPI) and targeted protein degraders (PROTACs). Because NFYA acts as the limiting, regulatory subunit of the NF-Y complex, blocking its interaction with the NFYB/NFYC dimer or inducing its degradation represents the most viable therapeutic avenue to shut down CCAAT-mediated oncogenic transcription. As first-generation chemical probes emerge, the next wave of R&D is targeting drug-resistant solid tumors with elevated metabolic plasticity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Early-stage Biotech | Triple-Negative Breast Cancer, Gastric Cancer | Trimerization Blockade Assay (Requires high-purity NFYA/B/C recombinant proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Colorectal Cancer, Hematological Malignancies | Degradation Kinetics & Rescue (Requires Lentivirus for stable reporter line construction) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Refractory Solid Tumors | In vitro Knockdown Validation (Requires sequence-verified siRNA sets as positive control) |